| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YJMCC.2016.08.003 |
| P698 | PubMed publication ID | 27497529 |
| P50 | author | Adrian Türkcan | Q59682438 |
| Bernhard Scharinger | Q63844578 | ||
| Hermann Stuppner | Q88168368 | ||
| Daniela Schuster | Q37376677 | ||
| Andreas Ritsch | Q43055662 | ||
| Herbert Oberacher | Q45409259 | ||
| Barbara Messner | Q57662955 | ||
| P2093 | author name string | Anna Vuorinen | |
| Michael Grimm | |||
| Philipp Eller | |||
| David Bernhard | |||
| Günther Laufer | |||
| Florian Pitterl | |||
| Kathrin Arnhard | |||
| Katharina Heinz | |||
| P2860 | cites work | The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease | Q70309305 |
| Statin trials and goals of cholesterol-lowering therapy | Q74519752 | ||
| Effect of two intensive statin regimens on progression of coronary disease | Q82513300 | ||
| New Lignan, Benzofuran, and Sesquiterpene Derivatives from the Roots of Leontopodium alpinum and L. leontopodioides | Q104955864 | ||
| The Protein Data Bank | Q24515306 | ||
| Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism | Q24603957 | ||
| The LDL receptor | Q24658039 | ||
| Structural mechanism for statin inhibition of HMG-CoA reductase | Q27631717 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis | Q28209813 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database | Q30494222 | ||
| Conformer generation with OMEGA: learning from the data set and the analysis of failures | Q30574063 | ||
| LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters | Q31143138 | ||
| Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors | Q34207135 | ||
| Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial | Q34501729 | ||
| Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study | Q34539702 | ||
| Efficient overlay of small organic molecules using 3D pharmacophores | Q34575180 | ||
| Clinical significance, pathogenesis, and management of postprandial hyperglycemia | Q35149496 | ||
| Mouse models for atherosclerosis and pharmaceutical modifiers. | Q36836487 | ||
| Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts. | Q37193530 | ||
| PPARγ signaling and metabolism: the good, the bad and the future | Q37407887 | ||
| The diabetogenic action of statins - mechanisms and clinical implications | Q38669513 | ||
| Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein | Q39016597 | ||
| Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels | Q39624057 | ||
| Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering | Q43516483 | ||
| Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols | Q43642121 | ||
| Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy | Q47933695 | ||
| P304 | page(s) | 35-46 | |
| P577 | publication date | 2016-08-03 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Leoligin, the major lignan from Edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE-/- mice | |
| P478 | volume | 99 |
Search more.